105 related articles for article (PubMed ID: 38717140)
1. B7-H3-Targeting Chimeric Antigen Receptors Epstein Barr Virus Specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3 Positive Solid Tumors.
Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
Cancer Res Commun; 2024 May; 4(6):1410-29. PubMed ID: 38717140
[TBL] [Abstract][Full Text] [Related]
2. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
[TBL] [Abstract][Full Text] [Related]
3. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins.
Qiao Y; Chen J; Wang X; Yan S; Tan J; Xia B; Chen Y; Lin K; Zou F; Liu B; He X; Zhang Y; Zhang X; Zhang H; Wu X; Lu L
Cancer Commun (Lond); 2023 Jul; 43(7):788-807. PubMed ID: 37282786
[TBL] [Abstract][Full Text] [Related]
6. A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma.
Wang L; Wang X; Wu Y; Wang J; Zhou W; Wang J; Guo H; Zhang N; Zhang L; Hu X; Zhao Y; Miao J; Zhang Z; Chard Dunmall LS; Zhang D; Lemoine NR; Cheng Z; Wang Y
Cancer Lett; 2023 Aug; 568():216303. PubMed ID: 37422126
[TBL] [Abstract][Full Text] [Related]
7. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
8. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
[TBL] [Abstract][Full Text] [Related]
9. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
[TBL] [Abstract][Full Text] [Related]
11. Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma.
Sakunrangsit N; Khuisangeam N; Inthanachai T; Yodsurang V; Taechawattananant P; Suppipat K; Tawinwung S
Cancer Immunol Immunother; 2024 Apr; 73(6):98. PubMed ID: 38619641
[TBL] [Abstract][Full Text] [Related]
12. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
[TBL] [Abstract][Full Text] [Related]
13. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
[TBL] [Abstract][Full Text] [Related]
14. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
[TBL] [Abstract][Full Text] [Related]
16. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
[TBL] [Abstract][Full Text] [Related]
17. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
[TBL] [Abstract][Full Text] [Related]
18. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cell with an Inducible Caspase 9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting.
Ventin M; Cattaneo G; Arya S; Jia J; Gelmi MC; Sun Y; Maggs L; Ksander BR; Verdijk RM; Boland GM; Jenkins RW; Haq R; Jager MJ; Wang X; Ryeom S; Ferrone CR
Clin Cancer Res; 2024 May; ():. PubMed ID: 38767611
[TBL] [Abstract][Full Text] [Related]
20. B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer.
Li S; Zhang M; Wang M; Wang H; Wu H; Mao L; Zhang M; Li H; Zheng J; Ma P; Wang G
Cell Death Discov; 2023 May; 9(1):147. PubMed ID: 37149721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
